Adverse events of Dupilumab in adults with moderate-to-severe atopic dermatitis: A meta-analysis

Dupilumab moderately reduced the risk of skin infection and the exacerbation of AD, slightly increased the risk of headache, and moderately increased the risk of injection-site reaction and conjunctivitis, but had little effect on other infections in adults with moderate-to-severe AD.